Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Legend Biotech Corporation before investing.

In this article, we go over a few key elements for understanding Legend Biotech Corporation’s stock price such as:

• Legend Biotech Corporation’s current stock price and volume
• Why Legend Biotech Corporation’s stock price changed recently
• Upgrades and downgrades for LEGN from analysts
• LEGN’s stock price momentum as measured by its relative strength

About Legend Biotech Corporation (LEGN)

Before we jump into Legend Biotech Corporation’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey.

Want to learn more about Legend Biotech Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Legend Biotech Corporation.

Legend Biotech Corporation’s Stock Price as of Market Close

As of December 02, 2025, 4:00 PM, CST, Legend Biotech Corporation’s stock price was $26.690.

Legend Biotech Corporation is down 0.56% from its previous closing price of $26.840.

During the last market session, Legend Biotech Corporation’s stock traded between $26.430 and $27.700. Currently, there are approximately 184.64 million shares outstanding for Legend Biotech Corporation.

Legend Biotech Corporation’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Legend Biotech Corporation Stock Price History

Legend Biotech Corporation’s (LEGN) price is currently down 3.68% so far this month.

During the month of December, Legend Biotech Corporation’s stock price has reached a high of $27.700 and a low of $26.430.

Over the last year, Legend Biotech Corporation has hit prices as high as $45.297 and as low as $25.710. Year to date, Legend Biotech Corporation’s stock is down 17.98%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Legend Biotech Corporation Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 01, 2025, there were analysts who downgraded Legend Biotech Corporation’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Legend Biotech Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Legend Biotech Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Legend Biotech Corporation’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Legend Biotech Corporation (LEGN) by visiting AAII Stock Evaluator.

Relative Price Strength of Legend Biotech Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 01, 2025, Legend Biotech Corporation has a weighted four-quarter relative price strength of -14.60%, which translates to a Momentum Score of 16 and is considered to be Very Weak.

Want to learn more about how Legend Biotech Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Legend Biotech Corporation Stock Price: Bottom Line

As of December 2, 2025, Legend Biotech Corporation’s stock price is $26.690, which is down 0.56% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Legend Biotech Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.